Anhui Shuangke Pharmaceutical Co., Ltd. was originally established on December 11, 2000. It is a modern pharmaceutical enterprise specializing in the research and development, production and sales of ophthalmic products.

The company has a registered capital of 20 million yuan and a total investment of 140 million yuan.

The company is located at No. 80, Science Avenue, High-tech Development Zone, Hefei City. It covers an area of 19,744.4 square meters, with a factory building area of 5,414 square meters, including a standardized GMP workshop area of 4,000 square meters. At present, it has a dosage form of eye drops, a fully automatic eye drop production line, a traditional Chinese medicine pretreatment workshop and an API workshop supporting the eye drop production line, with an annual output of 60 million pieces.

The company has passed the national GMP certification and acceptance three times: in June 2004, it passed the GMP certification; in May 2009, it passed the GMP re-certification again, and the eye drops were included in the sterile preparation management for the first time; The first company in the province passed the new GMP certification for eye drops.

The company now has 15 eye drop products with 18 specifications, including 3 national-level new drugs.

1. Zhuning-Gatisa New Eye Drops: New drugs: Class 2 chemical drugs, fourth-generation quinolone antibiotics, the first imitation variety in the country.

2. Zeshuang-Sorbitol Eye Drops: New drugs: Class 2 chemical drugs, artificial tears, exclusively produced nationwide.

3. Zhenmingliang-Jinzhen Eye Drops: New drugs: three types of traditional Chinese medicines, national patent protection for 20 years, and nationally exclusive production.

4. Runqing - Compound Dextran 70 Eye Drops: artificial tears, the country's exclusive specifications, exclusive production.

5. Runze-Primilast Potassium Eye Drops: Anti-allergic drug, produced by two companies nationwide;

6. Zeliang-benzdalysine eye drops: OTC products, which are produced by 5 companies in the country and are all raw materials and preparations.

There are 10 general medicines: including antibiotics, antiviral, treatment of spring catarrhal keratitis, treatment of glaucoma and varieties of mydriasis and regulation of paralysis.

The production of ophthalmic drugs requires sterility, high technical content, and a clean and environmentally friendly production environment. Due to the good variety structure of the company (low input and high output), with the continuous improvement of people's living standards, the market sales volume is getting larger and larger. It is a dosage form that is rapidly developing in the pharmaceutical field. The company is in a leading position in the ophthalmic medicine production industry in terms of hardware construction, production scale and technical level.